Wolverine

Wolverine is a vendor name, not a scientific or regulatory term, for a mixture of BPC-157 and TB-500 sold together in one vial. There is no standard formulation: ratios of 1:1 and 1:2 (favoring TB-500) both circulate, sometimes from the same supplier line. Only one study has ever tested the two peptides together, in rats, and the combination did not outperform TB-500 given alone. No clinical trial of the combination exists.

Research snapshot

Peptide category	Two-component peptide blend (BPC-157 + TB-500)
Primary research interest	Soft-tissue injury and tendon repair (as claimed by name; not established for the combination)
Highest available evidence	One published animal study of the combination
Human research available	No, no trial of the combination in humans exists or is registered
Development status	Not a formulated drug product; a compounding/vendor mixture only
Regulatory status	Neither component approved for human use anywhere; FDA nominations for both were withdrawn in April 2026

Technical identity (composition)

Primary name	Wolverine
Alternative names	None beyond the vendor marketing name itself; not a chemical or regulatory term
Composition	BPC-157 5 mg or 10 mg + TB-500 5 mg or 10 mg, no standard formulation; 1:1 and 1:2 (favoring TB-500) ratios both circulate
Share of vial by mass	~50%/50% (1:1 convention) or ~33%/67% BPC-157/TB-500 (1:2 convention)
Peptide sequence	Not applicable, a two-component mixture; see each component’s own entry for its sequence
Molecular formula	Not applicable, a multi-component mixture
CAS Registry Number	Not applicable, a multi-component mixture, not a single registered substance
Chemical modifications	Not applicable at the blend level; see each component’s own entry
Peptide class	Vendor-formulated multi-peptide mixture
Primary biological target	Multiple, inherits each component’s own separately-proposed target (see each component’s entry)
Developer or originator	Not a formal pharmaceutical development program, a research-chemical/compounding vendor mixture
Development status	Not in any clinical development pathway

What it is

Wolverine is a vendor name for a two-peptide mixture of BPC-157 and TB-500 in one vial. It is not a formulation with a specification, a manufacturer or a defined ratio. It is a product name that different suppliers apply to their own mixtures.

Two ratio conventions circulate. The more common is 1:1, usually 5 mg of each in a 10 mg vial, or 10 mg of each in a 20 mg vial. The other favours TB-500 at 1:2, commonly 5 mg of BPC-157 to 10 mg of TB-500 in a 3 mL vial. A vial bought on the strength of one convention may contain the other.

The name has no relationship to anything in the research literature. It comes from the comic book character, and it is doing the work of a claim without making one.

Potential benefits and research applications

Combined injury and tendon recovery (the marketed premise)

What is being investigated: whether combining BPC-157 and TB-500 improves soft-tissue and tendon healing outcomes beyond either peptide alone. How the effect might occur: through hypothesized complementary mechanisms, angiogenesis and growth-factor signaling from BPC-157, actin-regulation and cell-migration effects from TB-500. Evidence: one published animal study directly tested this combination. Strength: weak, the one test that exists found no additive benefit. Limitation: a single study, 8 animals per group, one species, one model, one route (intraperitoneal, not the subcutaneous route people actually use), is not enough to draw a conclusion in either direction, but it is also the entirety of the evidence, and what exists points against added benefit rather than toward it.

Everything each component is separately proposed for

Because the blend combines two peptides each already marketed for a wide range of uses, see the BPC-157 and TB-500 entries on this site for full detail, vendors sometimes imply the blend inherits all of those individually proposed benefits. It does not automatically do so; combining two unproven applications does not establish either one, let alone both together.

What dosage information circulates?

Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.

Reported use or research objective	Route reported	Amount reported	Frequency reported	Reported duration	Evidence or source category
Combination, rat Achilles tendon repair	Intraperitoneal	BPC-157 10 mcg/kg/day + TB-500 60 mcg/kg/day	Daily	4 weeks	Published animal research (Bicer et al., 2026)
Injury/recovery (blend as sold)	Subcutaneous	~1 mg of the mixture	Once daily	4–12 weeks	Community/vendor reported
BPC-157 component (as part of blend)	Subcutaneous	250–500 mcg	Once daily	4–12 weeks	Community/vendor reported
TB-500 component (as part of blend)	Subcutaneous	2–5 mg	Once or twice weekly	4–12 weeks	Community/vendor reported

Not consistently reported: any blend-specific human dosage; any evidence that either circulating ratio (1:1 or 1:2) has a documented rationale. The BPC-157 convention calls for daily dosing while the TB-500 convention calls for once- or twice-weekly dosing, a fixed-ratio vial cannot satisfy both separately-circulating schedules at once, and no vendor material addresses this.

What is known about the combination

One study has tested BPC-157 and TB-500 together in a living animal. In July 2026 a Turkish group transected and repaired the Achilles tendon in thirty-two rats across four groups of eight: control, BPC-157 alone at 10 micrograms per kilogram per day, TB-500 alone at 60 micrograms per kilogram per day, and both. Intraperitoneal, four weeks.

The result matters and it is not the one the name implies. TB-500 alone reached significance on maximum load to failure and on the total Bonar score. BPC-157 alone did not reach significance on any primary measure. And the combination arm did not outperform TB-500 alone on the measures that reached significance.

So the only in vivo test of this combination found no additive benefit from combining, and found that one of the two components carried whatever effect there was. Eight animals per group, one model, one species, by a route nobody uses. That is the entire evidence base for the blend.

No clinical trial of any BPC-157 and TB-500 combination exists, and no registered trial of one was found on ClinicalTrials.gov.

What the component evidence actually says

Both components have their own entries on this site and both are worth reading before the blend makes sense. In brief:

• BPC-157 has no identified receptor after roughly 230 published papers, about 77 percent of which come from one laboratory in Zagreb. Its three published human reports come from one clinic in Florida, thirty-one patients in total, none with a control group. The one independent in vivo test of its flagship tendon claim, at the original dose and route, is the study described above, and it missed significance.
• TB-500 is not thymosin beta-4. It is a seven amino acid fragment of it, and FDA states plainly that no information exists in the medical literature where TB-500 was given to a patient for any condition. Its own flagship preclinical result used a chemically different, non-acetylated peptide. When TB-500 itself was tested in a wound assay it was inactive, and only a shorter breakdown product showed activity.

Putting two compounds in a vial does not combine their evidence. It combines their unknowns, and adds the interaction between them, which nobody has studied.

What is not known

Whether the two peptides are stable in the same solution. Whether either degrades faster in the presence of the other. Whether the ratio matters. Whether any of the circulating ratio conventions has a basis. Whether the combination does anything a single component would not. Nothing in the published record addresses any of those questions.

Add to that everything unknown about each component separately, which on the BPC-157 side includes carcinogenicity, immunogenicity and human pharmacokinetics, and on the TB-500 side includes the entire toxicology package.

Regulatory status

Neither component is an approved drug anywhere. Both were the subject of FDA nominations that were later withdrawn, with immunogenicity noted as the concern, and withdrawal is not a clearance. Both were recommended for the 503A compounding list by the advisory committee in July 2026, against FDA staff, and FDA has not acted on either recommendation.

On anti-doping, TB-500 is named in WADA section S2.3 as a derivative of thymosin beta-4 and is prohibited at all times. BPC-157 falls under class S0 as a non-approved substance. Both are detectable in urine. A Canadian volleyball athlete received a four-year sanction in 2024 for using this exact pair.

Frequently asked questions

What is the Wolverine peptide blend?

A vendor-named mixture of BPC-157 and TB-500 in one vial, with no fixed or regulated ratio.

Is there a standard Wolverine dose?

No. Vendors state varying ratios, commonly 1:1 or 1:2 favoring TB-500, and no clinical dosing standard exists for the combination.

Has the combination been studied?

Once, in rats. The combination did not outperform TB-500 given alone.

Has it been studied in humans?

No. No clinical trial of the combination exists or is registered.

Why is it called Wolverine?

After the Marvel character known for rapid healing, a marketing reference, not a scientific one.

Is Wolverine the same as KLOW or GLOW?

No. KLOW adds GHK-Cu and KPV to this pair; GLOW adds GHK-Cu without KPV. Wolverine contains neither GHK-Cu nor KPV.

What routes are reported?

The one animal study used intraperitoneal injection; community-reported use is almost entirely subcutaneous.

Is Wolverine approved for any use?

No. Neither component is an approved drug anywhere.

What remains unknown?

Whether the two peptides are stable together, whether either circulating ratio has a basis, whether combining them adds any benefit over either alone (the one test found none), and the full safety profile of each component individually.

Bottom line

“Wolverine” is a marketing name, not a scientific or regulatory term, for a BPC-157/TB-500 mixture whose ratio varies by supplier. The single controlled study that has ever tested the combination found no benefit from combining the two beyond what TB-500 provided alone, a result that runs directly against the premise the name implies. No clinical trial of the combination exists. What circulates online is entirely vendor- and community-reported, built by simply combining each peptide’s own separately invented dosing conventions, which conflict with each other on frequency and cannot both be satisfied by one fixed-ratio vial. Both components remain unapproved for human use, and TB-500 is explicitly banned in sport.